CADTH Canadian Drug Expert Committee recommendation. indication: relapsing-remitting multiple sclerosis. Daclizumab (Zinbryta -- Biogen Canada Inc.) :
The Canadian Drug Expert Committee (CDEC) recommends that Daclizumab be reimbursed for the treatment of adult patients with active relapsing-remitting multiple sclerosis (RRMS) who have had an inadequate response to, or who are unable to tolerate, one or more therapies indicated for the treatment of...
Saved in:
| Corporate Author: | |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
[Ottawa, Ontario] :
Canadian Agency for Drugs and Technologies in Health,
June 2017.
|
| Edition: | Version 1.0. |
| Series: | Common drug review clinical review report.
|
| Subjects: | |
| Online Access: | http://www.ncbi.nlm.nih.gov/books/NBK535204/ Full text |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | 0d05c3ce-ad88-4f43-851c-8aa0d16cdb87 | ||
| 005 | 20240722000000.0 | ||
| 008 | 190102s2017 onc o 000 0 eng | ||
| 035 | |a (DNLM)BKSHLF:NBK535204 | ||
| 035 | |9 101740892 | ||
| 035 | |a 1740892 | ||
| 040 | |a DNLM |b eng |e rda |c DNLM |d UtOrBLW | ||
| 041 | 0 | 9 | |a eng |
| 042 | |a pcc | ||
| 043 | |a n-cn--- | ||
| 044 | |9 Canada | ||
| 060 | 0 | 0 | |a WL 360 |
| 110 | 2 | |a CADTH Canadian Drug Expert Committee, |e author. |0 n 2019180882 | |
| 245 | 1 | 0 | |a CADTH Canadian Drug Expert Committee recommendation. |p Daclizumab (Zinbryta -- Biogen Canada Inc.) : |b indication: relapsing-remitting multiple sclerosis. |
| 246 | 1 | |a Daclizumab (Zinbryta -- Biogen Canada Inc.) | |
| 246 | 1 | |a Drug reimbursement recommendation Daclizumab (Zinbryta) | |
| 250 | |a Version 1.0. | ||
| 264 | 1 | |a [Ottawa, Ontario] : |b Canadian Agency for Drugs and Technologies in Health, |c June 2017. | |
| 300 | |a 1 online resource (1 PDF file (7 pages)). | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a CADTH common drug review | |
| 500 | |a "Final." | ||
| 520 | |a The Canadian Drug Expert Committee (CDEC) recommends that Daclizumab be reimbursed for the treatment of adult patients with active relapsing-remitting multiple sclerosis (RRMS) who have had an inadequate response to, or who are unable to tolerate, one or more therapies indicated for the treatment of multiple sclerosis, if the following conditions are met: conditions: patient under the care of a specialist with experience in the diagnosis and management of RRMS; reduction in price of at least 25%. | ||
| 536 | |a Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec. | ||
| 588 | |a Description based on online resource; title from PDF title page (viewed March 5, 2019). | ||
| 650 | 1 | 2 | |a Multiple Sclerosis, Relapsing-Remitting |x drug therapy. |0 D020529Q000188 |
| 650 | 1 | 2 | |a Daclizumab |x therapeutic use. |0 D000077561Q000627 |
| 650 | 2 | 2 | |a Daclizumab |x economics. |0 D000077561Q000191 |
| 650 | 2 | 2 | |a Daclizumab |x administration & dosage. |0 D000077561Q000008 |
| 650 | 2 | 2 | |a Insurance, Health, Reimbursement |x economics. |0 D007349Q000191 |
| 650 | 2 | 2 | |a Cost-Benefit Analysis. |0 D003362 |
| 651 | 2 | |a Canada. |0 D002170 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e issuing body. |0 n 2007182676 | |
| 830 | 0 | |a Common drug review clinical review report. |0 n 2014186107 | |
| 856 | 4 | 0 | |u http://www.ncbi.nlm.nih.gov/books/NBK535204/ |t 0 |
| 856 | 4 | 0 | |t 0 |u https://www.ncbi.nlm.nih.gov/books/NBK535204/ |y Full text |
| 999 | 1 | 0 | |i 0d05c3ce-ad88-4f43-851c-8aa0d16cdb87 |l p2436585 |s US-MBP |m cadth_canadian_drug_expert_committee_recommendationindication_relapsin_____2017____1__canada________________________________________cadth_canadian_drug________________e |
| 999 | 1 | 1 | |l p2436585 |s ISIL:US-MBP |i MCPHS |t BKS |a E-Collections |c NCBI |d Other scheme |p UNLOANABLE |